Cargando…

The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention

BACKGROUND: The role of myocardial perfusion scintigraphy (MPS) in the follow-up of asymptomatic patients after percutaneous coronary intervention (PCI) is not established. OBJECTIVES: To evaluate the prognostic value and clinical use of MPS in asymptomatic patients after PCI. METHODS: Patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: de Andrade, Larissa Franco, Souza, Ana Carolina, Peclat, Thais, Bartholo, Caio, Pavanelo, Thalita, Lima, Ronaldo de Souza Leão
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Cardiologia - SBC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263458/
https://www.ncbi.nlm.nih.gov/pubmed/30517374
http://dx.doi.org/10.5935/abc.20180199
_version_ 1783375297952874496
author de Andrade, Larissa Franco
Souza, Ana Carolina
Peclat, Thais
Bartholo, Caio
Pavanelo, Thalita
Lima, Ronaldo de Souza Leão
author_facet de Andrade, Larissa Franco
Souza, Ana Carolina
Peclat, Thais
Bartholo, Caio
Pavanelo, Thalita
Lima, Ronaldo de Souza Leão
author_sort de Andrade, Larissa Franco
collection PubMed
description BACKGROUND: The role of myocardial perfusion scintigraphy (MPS) in the follow-up of asymptomatic patients after percutaneous coronary intervention (PCI) is not established. OBJECTIVES: To evaluate the prognostic value and clinical use of MPS in asymptomatic patients after PCI. METHODS: Patients who underwent MPS consecutively between 2008 and 2012 after PCI were selected. The MPS were classified as normal and abnormal, the perfusion scores, summed stress score (SSS), and summed difference score (SDS) were calculated and converted into percentage of total perfusion defect and ischemic defect. The follow-up was undertaken through telephone interviews and consultation with the Mortality Information System. Primary endpoints were death, cardiovascular death, and nonfatal acute myocardial infarction (AMI), and secondary endpoint was revascularization. Logistic regression and COX method were used to identify the predictors of events, and the value of p < 0.05 was considered statistically significant. RESULTS: A total of 647 patients were followed for 5.2 ± 1.6 years. 47% of MPS were normal, 30% were abnormal with ischemia, and 23% were abnormal without ischemia. There were 61 deaths, 27 being cardiovascular, 19 non-fatal AMI, and 139 revascularizations. The annual death rate was higher in those with abnormal perfusion without ischemia compared to the groups with ischemia and normal perfusion (3.3% × 2% × 1.2%, p = 0.021). The annual revascularization rate was 10.3% in the ischemia group, 3.7% in those with normal MPS, and 3% in those with abnormal MPS without ischemia. The independent predictors of mortality and revascularization were, respectively, total perfusion defect greater than 6%, and ischemic defect greater than 3%. Forty-two percent of the patients underwent MPS less than 2 years after PCI, and no significant differences were observed in relation to those who underwent it after that period. CONCLUSION: Although this information is not contemplated in guidelines, in this study MPS was able to predict events in asymptomatic after PCI patients, regardless of when they were performed.
format Online
Article
Text
id pubmed-6263458
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Sociedade Brasileira de Cardiologia - SBC
record_format MEDLINE/PubMed
spelling pubmed-62634582018-12-05 The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention de Andrade, Larissa Franco Souza, Ana Carolina Peclat, Thais Bartholo, Caio Pavanelo, Thalita Lima, Ronaldo de Souza Leão Arq Bras Cardiol Original Article BACKGROUND: The role of myocardial perfusion scintigraphy (MPS) in the follow-up of asymptomatic patients after percutaneous coronary intervention (PCI) is not established. OBJECTIVES: To evaluate the prognostic value and clinical use of MPS in asymptomatic patients after PCI. METHODS: Patients who underwent MPS consecutively between 2008 and 2012 after PCI were selected. The MPS were classified as normal and abnormal, the perfusion scores, summed stress score (SSS), and summed difference score (SDS) were calculated and converted into percentage of total perfusion defect and ischemic defect. The follow-up was undertaken through telephone interviews and consultation with the Mortality Information System. Primary endpoints were death, cardiovascular death, and nonfatal acute myocardial infarction (AMI), and secondary endpoint was revascularization. Logistic regression and COX method were used to identify the predictors of events, and the value of p < 0.05 was considered statistically significant. RESULTS: A total of 647 patients were followed for 5.2 ± 1.6 years. 47% of MPS were normal, 30% were abnormal with ischemia, and 23% were abnormal without ischemia. There were 61 deaths, 27 being cardiovascular, 19 non-fatal AMI, and 139 revascularizations. The annual death rate was higher in those with abnormal perfusion without ischemia compared to the groups with ischemia and normal perfusion (3.3% × 2% × 1.2%, p = 0.021). The annual revascularization rate was 10.3% in the ischemia group, 3.7% in those with normal MPS, and 3% in those with abnormal MPS without ischemia. The independent predictors of mortality and revascularization were, respectively, total perfusion defect greater than 6%, and ischemic defect greater than 3%. Forty-two percent of the patients underwent MPS less than 2 years after PCI, and no significant differences were observed in relation to those who underwent it after that period. CONCLUSION: Although this information is not contemplated in guidelines, in this study MPS was able to predict events in asymptomatic after PCI patients, regardless of when they were performed. Sociedade Brasileira de Cardiologia - SBC 2018-12 /pmc/articles/PMC6263458/ /pubmed/30517374 http://dx.doi.org/10.5935/abc.20180199 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
de Andrade, Larissa Franco
Souza, Ana Carolina
Peclat, Thais
Bartholo, Caio
Pavanelo, Thalita
Lima, Ronaldo de Souza Leão
The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention
title The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention
title_full The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention
title_fullStr The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention
title_full_unstemmed The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention
title_short The Prognostic Value and Clinical Use of Myocardial Perfusion Scintigraphy in Asymptomatic Patients after Percutaneous Coronary Intervention
title_sort prognostic value and clinical use of myocardial perfusion scintigraphy in asymptomatic patients after percutaneous coronary intervention
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263458/
https://www.ncbi.nlm.nih.gov/pubmed/30517374
http://dx.doi.org/10.5935/abc.20180199
work_keys_str_mv AT deandradelarissafranco theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT souzaanacarolina theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT peclatthais theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT bartholocaio theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT pavanelothalita theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT limaronaldodesouzaleao theprognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT deandradelarissafranco prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT souzaanacarolina prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT peclatthais prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT bartholocaio prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT pavanelothalita prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention
AT limaronaldodesouzaleao prognosticvalueandclinicaluseofmyocardialperfusionscintigraphyinasymptomaticpatientsafterpercutaneouscoronaryintervention